Regenicin

Overview

Regenicin’s cultured skin substitute, NovaDerm®, is a living, bilayer tissue designed to promote burn healing. The process begins by harvesting a small, full-thickness skin sample from the patient. From this sample, two types of skin cells are isolated: keratinocytes (epidermal cells) and fibroblasts (dermal cells). These cells are cultured separately in specialized nutrient media at a cell therapy facility, where the cell populations are expanded to create multiple grafts. The expanded cells are then combined with a proprietary collagen biopolymer substrate, where they are organized on the absorbable scaffold to create a structure that mimics natural skin architecture with both epidermal and dermal layers. Once complete, the skin substitute is shipped to the clinical site, where surgeons graft it onto the patient’s burn areas. This approach has demonstrated effectiveness in generating a functional skin barrier in preclinical studies and has successfully promoted wound closure and healing in clinical studies. The key advantage of this technology is that multiple grafts can be produced from a single small skin sample, making it an efficient solution for treating large burn areas.